1519 related articles for article (PubMed ID: 26997539)
21. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
[TBL] [Abstract][Full Text] [Related]
22. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P
World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
Castera L
Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
[TBL] [Abstract][Full Text] [Related]
26. Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?
Ajmera V; Loomba R
Semin Liver Dis; 2018 Feb; 38(1):14-20. PubMed ID: 29471562
[TBL] [Abstract][Full Text] [Related]
27. The epidemiology of non-alcoholic fatty liver disease.
Bellentani S
Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
[TBL] [Abstract][Full Text] [Related]
28. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
Younossi ZM; Noureddin M; Bernstein D; Kwo P; Russo M; Shiffman ML; Younes Z; Abdelmalek M
Am J Gastroenterol; 2021 Feb; 116(2):254-262. PubMed ID: 33284184
[TBL] [Abstract][Full Text] [Related]
29. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
30. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
[TBL] [Abstract][Full Text] [Related]
31. The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.
Balakrishnan M; Loomba R
J Clin Gastroenterol; 2020 Feb; 54(2):107-113. PubMed ID: 31789757
[TBL] [Abstract][Full Text] [Related]
32. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
[TBL] [Abstract][Full Text] [Related]
33. Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease.
Gallego-Durán R; Cerro-Salido P; Gomez-Gonzalez E; Pareja MJ; Ampuero J; Rico MC; Aznar R; Vilar-Gomez E; Bugianesi E; Crespo J; González-Sánchez FJ; Aparcero R; Moreno I; Soto S; Arias-Loste MT; Abad J; Ranchal I; Andrade RJ; Calleja JL; Pastrana M; Iacono OL; Romero-Gómez M
Sci Rep; 2016 Aug; 6():31421. PubMed ID: 27514671
[TBL] [Abstract][Full Text] [Related]
34. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
35. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
[TBL] [Abstract][Full Text] [Related]
36. Advances in ultrasound elastography for nonalcoholic fatty liver disease.
Yoneda M; Honda Y; Nogami A; Imajo K; Nakajima A
J Med Ultrason (2001); 2020 Oct; 47(4):521-533. PubMed ID: 32748075
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and diagnosis of NAFLD/NASH.
Hashimoto E; Taniai M; Tokushige K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
[TBL] [Abstract][Full Text] [Related]
38. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future.
Araújo AR; Rosso N; Bedogni G; Tiribelli C; Bellentani S
Liver Int; 2018 Feb; 38 Suppl 1():47-51. PubMed ID: 29427488
[TBL] [Abstract][Full Text] [Related]
39. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
[TBL] [Abstract][Full Text] [Related]
40. Non-alcoholic fatty liver infiltration in children: an underdiagnosed evolving disease.
Tzifi F; Fretzayas A; Chrousos G; Kanaka-Gantenbein C
Hormones (Athens); 2019 Sep; 18(3):255-265. PubMed ID: 31140156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
